SPTBN1
Spectrin beta chain, non-erythrocytic 1
Also known as: SPTB2_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q01082
- Gene
- SPTBN1
- Ensembl
- ENSG00000115306
- Chromosome
- 2
- Canonical length
- 2364 aa
- Protein class
- Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters
- Subcellular location
- Cytosol
OverviewNCBI Gene
Spectrin is an actin crosslinking and molecular scaffold protein that links the plasma membrane to the actin cytoskeleton, and functions in the determination of cell shape, arrangement of transmembrane proteins, and organization of organelles. It is composed of two antiparallel dimers of alpha- and beta- subunits. This gene is one member of a family of beta-spectrin genes. The encoded protein contains an N-terminal actin-binding domain, and 17 spectrin repeats which are involved in dimer formation. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
2364 residues, UniProt reviewed canonical sequence.
>Q01082|SPTBN1
1 MTTTVATDYD NIEIQQQYSD VNNRWDVDDW DNENSSARLF ERSRIKALAD EREAVQKKTF
61 TKWVNSHLAR VSCRITDLYT DLRDGRMLIK LLEVLSGERL PKPTKGRMRI HCLENVDKAL
121 QFLKEQRVHL ENMGSHDIVD GNHRLTLGLI WTIILRFQIQ DISVETEDNK EKKSAKDALL
181 LWCQMKTAGY PNVNIHNFTT SWRDGMAFNA LIHKHRPDLI DFDKLKKSNA HYNLQNAFNL
241 AEQHLGLTKL LDPEDISVDH PDEKSIITYV VTYYHYFSKM KALAVEGKRI GKVLDNAIET
301 EKMIEKYESL ASDLLEWIEQ TIIILNNRKF ANSLVGVQQQ LQAFNTYRTV EKPPKFTEKG
361 NLEVLLFTIQ SKMRANNQKV YMPREGKLIS DINKAWERLE KAEHERELAL RNELIRQEKL
421 EQLARRFDRK AAMRETWLSE NQRLVSQDNF GFDLPAVEAA TKKHEAIETD IAAYEERVQA
481 VVAVARELEA ENYHDIKRIT ARKDNVIRLW EYLLELLRAR RQRLEMNLGL QKIFQEMLYI
541 MDWMDEMKVL VLSQDYGKHL LGVEDLLQKH TLVEADIGIQ AERVRGVNAS AQKFATDGEG
601 YKPCDPQVIR DRVAHMEFCY QELCQLAAER RARLEESRRL WKFFWEMAEE EGWIREKEKI
661 LSSDDYGKDL TSVMRLLSKH RAFEDEMSGR SGHFEQAIKE GEDMIAEEHF GSEKIRERII
721 YIREQWANLE QLSAIRKKRL EEASLLHQFQ ADADDIDAWM LDILKIVSSS DVGHDEYSTQ
781 SLVKKHKDVA EEIANYRPTL DTLHEQASAL PQEHAESPDV RGRLSGIEER YKEVAELTRL
841 RKQALQDTLA LYKMFSEADA CELWIDEKEQ WLNNMQIPEK LEDLEVIQHR FESLEPEMNN
901 QASRVAVVNQ IARQLMHSGH PSEKEIKAQQ DKLNTRWSQF RELVDRKKDA LLSALSIQNY
961 HLECNETKSW IREKTKVIES TQDLGNDLAG VMALQRKLTG MERDLVAIEA KLSDLQKEAE
1021 KLESEHPDQA QAILSRLAEI SDVWEEMKTT LKNREASLGE ASKLQQFLRD LDDFQSWLSR
1081 TQTAIASEDM PNTLTEAEKL LTQHENIKNE IDNYEEDYQK MRDMGEMVTQ GQTDAQYMFL
1141 RQRLQALDTG WNELHKMWEN RQNLLSQSHA YQQFLRDTKQ AEAFLNNQEY VLAHTEMPTT
1201 LEGAEAAIKK QEDFMTTMDA NEEKINAVVE TGRRLVSDGN INSDRIQEKV DSIDDRHRKN
1261 RETASELLMR LKDNRDLQKF LQDCQELSLW INEKMLTAQD MSYDEARNLH SKWLKHQAFM
1321 AELASNKEWL DKIEKEGMQL ISEKPETEAV VKEKLTGLHK MWEVLESTTQ TKAQRLFDAN
1381 KAELFTQSCA DLDKWLHGLE SQIQSDDYGK DLTSVNILLK KQQMLENQME VRKKEIEELQ
1441 SQAQALSQEG KSTDEVDSKR LTVQTKFMEL LEPLNERKHN LLASKEIHQF NRDVEDEILW
1501 VGERMPLATS TDHGHNLQTV QLLIKKNQTL QKEIQGHQPR IDDIFERSQN IVTDSSSLSA
1561 EAIRQRLADL KQLWGLLIEE TEKRHRRLEE AHRAQQYYFD AAEAEAWMSE QELYMMSEEK
1621 AKDEQSAVSM LKKHQILEQA VEDYAETVHQ LSKTSRALVA DSHPESERIS MRQSKVDKLY
1681 AGLKDLAEER RGKLDERHRL FQLNREVDDL EQWIAEREVV AGSHELGQDY EHVTMLQERF
1741 REFARDTGNI GQERVDTVNH LADELINSGH SDAATIAEWK DGLNEAWADL LELIDTRTQI
1801 LAASYELHKF YHDAKEIFGR IQDKHKKLPE ELGRDQNTVE TLQRMHTTFE HDIQALGTQV
1861 RQLQEDAARL QAAYAGDKAD DIQKRENEVL EAWKSLLDAC ESRRVRLVDT GDKFRFFSMV
1921 RDLMLWMEDV IRQIEAQEKP RDVSSVELLM NNHQGIKAEI DARNDSFTTC IELGKSLLAR
1981 KHYASEEIKE KLLQLTEKRK EMIDKWEDRW EWLRLILEVH QFSRDASVAE AWLLGQEPYL
2041 SSREIGQSVD EVEKLIKRHE AFEKSAATWD ERFSALERLT TLELLEVRRQ QEEEERKRRP
2101 PSPEPSTKVS EEAESQQQWD TSKGEQVSQN GLPAEQGSPR MAETVDTSEM VNGATEQRTS
2161 SKESSPIPSP TSDRKAKTAL PAQSAATLPA RTQETPSAQM EGFLNRKHEW EAHNKKASSR
2221 SWHNVYCVIN NQEMGFYKDA KTAASGIPYH SEVPVSLKEA VCEVALDYKK KKHVFKLRLN
2281 DGNEYLFQAK DDEEMNTWIQ AISSAISSDK HEVSASTQST PASSRAQTLP TSVVTITSES
2341 SPGKREKDKE KDKEKRFSLF GKKKLocalizationUniProt · AlphaFold · HPA
Whether an antibody against SPTBN1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.34
- Highest tissue expression
- 176 nTPM
Expression across tissuesHPA
Tissue
- adipose tissue: 176 nTPM
- basal ganglia: 140 nTPM
- amygdala: 137 nTPM
- heart muscle: 127 nTPM
- lung: 124 nTPM
- parathyroid gland: 122 nTPM
Single-cell type
- adipocytes: 1,150 nCPM
- leydig cells: 934 nCPM
- vascular endothelial cells: 929 nCPM
- lymphatic endothelial cells: 919 nCPM
- fibro-adipogenic progenitors: 913 nCPM
- peritubular myoid cells: 879 nCPM
Immune cell
- NK-cell: 5.2 nTPM
- naive CD4 T-cell: 5 nTPM
- MAIT T-cell: 3.9 nTPM
- gdT-cell: 3.7 nTPM
- memory B-cell: 3.7 nTPM
- memory CD8 T-cell: 3.6 nTPM
Brain region
- thalamus: 679 nTPM
- amygdala: 652 nTPM
- basal ganglia: 635 nTPM
- cerebral cortex: 560 nTPM
- midbrain: 546 nTPM
- white matter: 542 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about SPTBN1.
Disease | AllUniProt
Conditions SPTBN1 is implicated in, by any mechanism.
- Developmental delay, impaired speech, and behavioral abnormalities (DDISBA) MIM:619475
Disease | GeneticClinVar
65 pathogenic / likely-pathogenic of 721 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Developmental delay, impaired speech, and behavioral abnormalities
- Inborn genetic diseases
- Neurodevelopmental disorder
- SPTBN1-related disorder
- Pervasive developmental disorder
ReferencesPubMed · IEDB
Publications for SPTBN1 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
2 publications
- Identification of IgA autoantibodies targeting mesangial cells redefines the pathogenesis of IgA nephropathy.
2023 · Sci Adv · RCR 6.9 · 59 citations - The Prevalence and Characteristics of IgA Antibodies to β2-Spectrin and CBX3 in Immunoglobulin A Nephropathy.
2025 · Kidney Int Rep · RCR 2.2 · 6 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.09
- gnomAD pLI
- 1
- gnomAD missense Z
- 4.54
- DepMap mean gene effect
- 0.08
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- actin cytoskeleton organization
- actin filament capping
- central nervous system development
- central nervous system formation
- Golgi to plasma membrane protein transport
- membrane assembly
- mitotic cytokinesis
- plasma membrane organization
- positive regulation of interleukin-2 production
- positive regulation of protein localization to plasma membrane
- protein localization to plasma membrane
- regulation of protein localization to plasma membrane
- regulation of SMAD protein signal transduction
Molecular functions
- actin binding
- actin filament binding
- ankyrin binding
- cadherin binding
- calmodulin binding
- GTPase binding
- phospholipid binding
- RNA binding
- structural constituent of cytoskeleton
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Actinin-type actin-binding domain, conserved site
- Pleckstrin homology domain, spectrin-type
- Calponin homology domain
- Pleckstrin homology domain
- Spectrin repeat
- PH-like domain superfamily
- Spectrin, beta subunit
- Spectrin/alpha-actinin
- CH domain superfamily
- Pleckstrin homology domain 9
- Calponin homology (CH) domain
- Spectrin repeat
- Pleckstrin homology domain
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of SPTBN1 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads SPTBN1 as an antibody target. Whether an autoantibody or antibody against SPTBN1 could matter depends on whether native SPTBN1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
SPTBN1 is annotated at the cell surface, where native SPTBN1 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label SPTBN1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...